Hereditary Cancer was Myriad Genetics’s largest product and service line in fiscal 2025, bringing in $372.40M of $824.50M (45%).
| Product and Service | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Diagnostic Testing | — | — | — | — | |||||||
| Molecular Diagnostic - Hereditary Cancer | — | — | — | — | |||||||
| Molecular Diagnostic - Hereditary Cancer Testing | — | — | — | — | |||||||
| Hereditary Cancer | $305.50M | $327.80M | $364.50M | $372.40M | |||||||
| Prenatal | $116.40M | $151.30M | $177.10M | $186.30M | |||||||
| Mental Health | — | $138.50M | $170.20M | $144.10M | |||||||
| Tumor Profiling | $128.60M | $135.60M | $125.80M | $121.70M | |||||||
| Molecular Diagnostic - Pharmacogenomics | — | — | — | — | |||||||
| Molecular Diagnostic - Prenatal | — | — | — | — | |||||||
| Molecular Diagnostic - Genesight | — | — | — | — | |||||||
| Pharmacogenomics | $127.60M | — | — | — | |||||||
| Molecular Diagnostic- Vectra | — | — | — | — | |||||||
| Molecular Diagnostic - Autoimmune | — | — | — | — | |||||||
| Pharmaceutical & Clinical Services | — | — | — | — | |||||||
| Molecular Diagnostic - Tumor Profiling | — | — | — | — | |||||||
| Other Revenue | — | — | — | — | |||||||
| Autoimmune | $300.00K | — | — | — | |||||||
| Molecular Diagnostic - Prolaris | — | — | — | — | |||||||
| Molecular Diagnostic - Endopredict | — | — | — | — | |||||||
| Molecular Diagnostic - Other | — | — | — | — | |||||||
| Other | — | — | — | — | |||||||
| Total | $678.40M | $753.20M | $837.60M | $824.50M |
Myriad Genetics brought in $824.50M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 1.6% from $837.60M in fiscal 2024. Hereditary Cancer was the largest at $372.40M (45.2%), ahead of Prenatal at $186.30M (22.6%) and Mental Health at $144.10M (17.5%). The remaining line, Tumor Profiling, brought in $121.70M.
Compared with fiscal 2024, Prenatal grew fastest, up 5.2% to $186.30M, while Mental Health fell the most, down 15.3% to $144.10M.
Myriad Genetics began breaking out Mental Health in fiscal 2023, when it brought in $138.50M. Myriad Genetics stopped reporting Pharmacogenomics ($127.60M in fiscal 2022) and Autoimmune ($300.00K in fiscal 2022) as separate lines.
U.S was Myriad Genetics’s largest region in fiscal 2025, bringing in $768.00M of $824.50M (93%).
| Geography | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| U.S | — | $671.70M | $769.50M | $768.00M | |||
| United States | $591.50M | — | — | — | |||
| Row | — | $81.50M | $68.10M | $56.50M | |||
| Rest Of World | $86.90M | — | — | — | |||
| Total | $678.40M | $753.20M | $837.60M | $824.50M |
Myriad Genetics brought in $824.50M from its two regions in fiscal 2025, the year ended December 31, 2025. That was down 1.6% from $837.60M in fiscal 2024. U.S was the largest at $768.00M (93.1%), ahead of Row at $56.50M (6.9%).
Compared with fiscal 2024, U.S fell 0.2% to $768.00M and Row fell 17.0% to $56.50M.
Myriad Genetics began breaking out U.S in fiscal 2023 and Row in fiscal 2023. Myriad Genetics stopped reporting United States ($591.50M in fiscal 2022) and Rest Of World ($86.90M in fiscal 2022) as separate regions.
As Reported was Myriad Genetics’s largest revenue line in fiscal 2017, bringing in $769.90M of $728.70M (106%).
| Initial Application Period Cumulative Effect Transition | FY 2017 |
|---|---|
| As Reported | $769.90M |
| Adjusted For Asc 606 | -$41.20M |
| Total | $728.70M |
Myriad Genetics brought in $728.70M from its two revenue lines in fiscal 2017, the year ended June 30, 2017. As Reported was the largest at $769.90M (105.7%).
The total is net of Adjusted For Asc 606, which took $41.20M off revenue in fiscal 2017.
Myriad Genetics (MYGN) reports its revenue by product and service, by geography and by initial application period cumulative effect transition. In fiscal 2025, Hereditary Cancer was its largest product and service line, bringing in $372.40M (45.2% of the total), followed by Prenatal at $186.30M (22.6%).
Hereditary Cancer was Myriad Genetics' largest product and service line in fiscal 2025, bringing in $372.40M, or 45.2% of the $824.50M total across its four product and service lines.
U.S was Myriad Genetics' largest region in fiscal 2025, bringing in $768.00M, or 93.1% of the $824.50M total across its two regions.
As Reported was Myriad Genetics' largest revenue line in fiscal 2017, bringing in $769.90M, or 105.7% of the $728.70M total across its two revenue lines.
Among Myriad Genetics' product and service lines that make up at least 2% of revenue, Prenatal grew fastest in fiscal 2025, up 5.2% from $177.10M to $186.30M.
Every figure comes from Myriad Genetics' annual financial filings, as reported. Each line keeps the name Myriad Genetics gives it, and years follow its fiscal calendar.
Myriad Genetics' revenue by product and service goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.